{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:04:06Z","timestamp":1785416646924,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.03.037","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:05:17Z","timestamp":1774973117000},"page":"997-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value\u2011Based Contracting for Cell and Gene Therapies: A Scoping Review of Payer-Manufacturer Agreements and Treatment Center Considerations in the United States"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-7520","authenticated-orcid":false,"given":"Pranav M.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4957-5476","authenticated-orcid":false,"given":"Amy Heck","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9971-2709","authenticated-orcid":false,"given":"Cynthia","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6712-9413","authenticated-orcid":false,"given":"Jason B.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulia","family":"Opran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4090-8457","authenticated-orcid":false,"given":"Chelsea Phillips","family":"Renfro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.03.037_bib0001","unstructured":"US Food and Drug Administration. Approved cellular and gene therapy products - Updated December 9, 2025. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed January 18, 2026."},{"issue":"1","key":"10.1016\/j.jtct.2026.03.037_bib0002","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drudis.2021.09.001","article-title":"Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues","volume":"27","author":"Young","year":"2022","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.jtct.2026.03.037_bib0003","article-title":"Updated: Most expensive drugs in the US in 2025","author":"Becker","year":"2025","journal-title":"FiercePharma"},{"issue":"5","key":"10.1016\/j.jtct.2026.03.037_bib0004","first-page":"410","article-title":"The current status of outcomes-based contracting for manufacturers and payers: an AMCP membership survey","volume":"24","author":"Duhig","year":"2018","journal-title":"J Manag Care Spec Pharm."},{"issue":"10","key":"10.1016\/j.jtct.2026.03.037_bib0005","first-page":"1018","article-title":"Outcomes-based contracting experience: research findings from US and European stakeholders","volume":"23","author":"Nazareth","year":"2017","journal-title":"J Manag Care Spec Pharm."},{"issue":"11","key":"10.1016\/j.jtct.2026.03.037_bib0006","first-page":"1174","article-title":"Regulatory, policy, and operational considerations for outcomes-based risk-sharing agreements in the US market: opportunities for reform","volume":"25","author":"Goodman","year":"2019","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.jtct.2026.03.037_bib0007","unstructured":"AMCP Value-Based Contracting Advisory Group. In the world of value-based care, words matter: A lexicon for value-based purchasing. August 2022. Available at: https:\/\/www.amcp.org\/sites\/default\/files\/2022-08\/VBCLexicon_0726.pdf. Accessed December 1, 2025."},{"issue":"7","key":"10.1016\/j.jtct.2026.03.037_bib0008","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for Scoping Reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med."},{"issue":"11","key":"10.1016\/j.jtct.2026.03.037_bib0009","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1377\/hlthaff.2023.00527","article-title":"Confronting high costs and clinical uncertainty: innovative payment models for gene therapies","volume":"42","author":"Horrow","year":"2023","journal-title":"Health Aff (Millwood)."},{"key":"10.1016\/j.jtct.2026.03.037_bib0010","article-title":"Innovative contracting for gene therapies: current landscape and perspectives on the future of gene therapy financing in the USA [e-pub ahead of print]","author":"Wagner","year":"2025","journal-title":"Pharmacoeconomics."},{"issue":"4","key":"10.1016\/j.jtct.2026.03.037_bib0011","article-title":"Blue Cross first to open sickle cell gene therapy floodgates","volume":"47","author":"Tepper","year":"2024","journal-title":"Crain\u2019s Chicago Business."},{"key":"10.1016\/j.jtct.2026.03.037_bib0012","article-title":"Bluebird Bio details plans for the commercial launch of LYFGENIA gene therapy for patients ages 12 and older with sickle cell disease and a history of vaso-occlusive events; Bluebird has set wholesale acquisition cost of LYFGENIA In U.S. at $3.1M","author":"Benzinga","year":"2023","journal-title":"Benzinga"},{"key":"10.1016\/j.jtct.2026.03.037_bib0013","unstructured":"BUSINESSWIRE. bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model. December 4, 2024. Available at: https:\/\/www.businesswire.com\/news\/home\/20241203868705\/en\/bluebird-bio-Confirms-Participation-in-Center-for-Medicare-and-Medicaid-Innovation-CMMI-Cell-and-Gene-Therapy-Access-Model. Accessed December 1, 2025."},{"issue":"11","key":"10.1016\/j.jtct.2026.03.037_bib0014","article-title":"Access & gene therapies: uncertainties impact commercial uptake","volume":"40","author":"Jayanthi","year":"2020","journal-title":"PharmExec."},{"issue":"11","key":"10.1016\/j.jtct.2026.03.037_bib0015","first-page":"38","article-title":"Accessibility and affordability of gene therapy","volume":"29","author":"Edlin","year":"2019","journal-title":"Managed Healthcare Executive (MHE)."},{"issue":"35","key":"10.1016\/j.jtct.2026.03.037_bib0016","first-page":"11","article-title":"Cigna aims to expand affordable access to gene therapies","volume":"49","author":"Livingston","year":"2019","journal-title":"Modern Healthcare."},{"issue":"12","key":"10.1016\/j.jtct.2026.03.037_bib0017","first-page":"22","article-title":"As a cure for high drug prices, outcomes-based deals aren\u2019t delivering yet","volume":"49","author":"Meyer","year":"2019","journal-title":"Modern Healthcare."},{"key":"10.1016\/j.jtct.2026.03.037_bib0018","article-title":"Spark, Glaxo gene therapies near $1 million \u2014 still a bargain?","author":"Gatlin","year":"2018","journal-title":"Investor\u2019s Business Daily"},{"key":"10.1016\/j.jtct.2026.03.037_bib0019","article-title":"How to cover Novartis\u2019 $475K CAR-T drug Kymriah? A \u2018new payment model\u2019 is the only way","author":"Weintraub","year":"2017","journal-title":"Express Scripts says. FiercePharma [online]"},{"key":"10.1016\/j.jtct.2026.03.037_bib0020","series-title":"value-based payment plan for breakthrough cancer drug","author":"drops","year":"2018"},{"key":"10.1016\/j.jtct.2026.03.037_bib0021","article-title":"CMS quietly cancels plan for indication-based pricing on Novartis","author":"Sagonowsky","year":"2018","journal-title":"Kymriah. FiercePharma [online]."},{"key":"10.1016\/j.jtct.2026.03.037_bib0022","unstructured":"Weintraub A. Novartis: Alternative payments will \u2018reset the paradigm\u2019 for covering gene, cell therapies. FiercePharma [online]. 2019 Available at: https:\/\/www.fiercepharma.com\/pharma\/alternative-payment-models-to-reset-paradigm-for-reimbursement-gene-and-cell-therapies. Accessed December 1, 2025"},{"key":"10.1016\/j.jtct.2026.03.037_bib0023","article-title":"Senate bill backed by patient groups proposes value-based \u201cannuity\u201d payments for pricey treatments","author":"Weintraub","year":"2019","journal-title":"FiercePharma [online]."},{"issue":"12","key":"10.1016\/j.jtct.2026.03.037_bib0024","first-page":"20","article-title":"Access and reimbursement for adoptive T-cell transfer drugs","volume":"37","author":"Favaro","year":"2017","journal-title":"PharmExec.com"},{"issue":"11","key":"10.1016\/j.jtct.2026.03.037_bib0025","first-page":"1096","article-title":"Advancing Value-Based Contracting","volume":"23","year":"2017","journal-title":"J Manag Care Spec Pharm."},{"key":"10.1016\/j.jtct.2026.03.037_bib0026","unstructured":"Dodda S, Hikmat Z, Sugarman R, et al. US payer perceptions of innovative contracts with cell and gene therapies. Presented at Academy of Managed Care Pharmacy 2023 Annual Meeting. Available at: https:\/\/www.amerisourcebergen.com\/-\/media\/assets\/xcenda\/english\/content-assets\/conference-and-poster-presentations\/2023\/innovative-cgt-contracts_poster_amcp-2023.pdf. Accessed January 18, 2026."},{"key":"10.1016\/j.jtct.2026.03.037_bib0027","article-title":"Health plan interest in outcomes-based contracts increasing","author":"Alwardt","year":"2018","journal-title":"Avalere Health"},{"key":"10.1016\/j.jtct.2026.03.037_bib0028","article-title":"More than half of health plans use outcomes-based contracts","author":"Alwardt","year":"2019","journal-title":"Avalere Health"},{"issue":"2","key":"10.1016\/j.jtct.2026.03.037_bib0029","first-page":"70","article-title":"Value-based arrangements may be more prevalent than assumed","volume":"25","author":"Mahendraratnam","year":"2019","journal-title":"Am J Manag Care."},{"key":"10.1016\/j.jtct.2026.03.037_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2026.01.002","article-title":"From vision to viability: developing infrastructure for cell and gene therapy programs [e-pub ahead of print]","author":"Mahmoudjafari","year":"2026","journal-title":"Transplant Cell Ther."},{"issue":"5","key":"10.1016\/j.jtct.2026.03.037_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104337","article-title":"Long-term follow-up after authorization of gene therapy: leveraging real-world data","volume":"30","author":"de Haart","year":"2025","journal-title":"Drug Discov Today."},{"issue":"8","key":"10.1016\/j.jtct.2026.03.037_bib0032","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther."},{"issue":"2 suppl","key":"10.1016\/j.jtct.2026.03.037_bib0033","doi-asserted-by":"crossref","first-page":"S385","DOI":"10.1016\/j.jtct.2023.12.539","article-title":"Carvykti (cilta-cel) real world outcomes across the Sarah Cannon Transplant Cell Therapy Network","volume":"30","author":"Gregory","year":"2024","journal-title":"Transplant Cell Ther."},{"issue":"2","key":"10.1016\/j.jtct.2026.03.037_bib0034","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.jtct.2025.01.367","article-title":"Real world outcomes of CAR T-cell therapy for B-cell lymphoma in adults age \u2265 65: a referral center experience","volume":"31","author":"Vegel","year":"2025","journal-title":"Transplant Cell Ther."},{"issue":"16","key":"10.1016\/j.jtct.2026.03.037_bib0035","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","article-title":"Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention","volume":"8","author":"Furqan","year":"2024","journal-title":"Blood Adv."},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.03.037_bib0036","doi-asserted-by":"crossref","first-page":"8056","DOI":"10.1182\/blood-2025-8056","article-title":"Real-world outcomes of autologous CD19-directed CAR T-cell therapy in relapsed\/refractory large B-cell lymphoma: a single-center experience","volume":"146","author":"Zhang","year":"2025","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2026.03.037_bib0037","unstructured":"Huang D, Mohammed R. Exploring the trend of value-based contracts in the US. Available at: https:\/\/forhealthconsulting.umassmed.edu\/exploring-the-trend-of-value-based-contracts-in-the-united-states\/. Accessed January 18, 2026."},{"issue":"suppl 1","key":"10.1016\/j.jtct.2026.03.037_bib0038","doi-asserted-by":"crossref","first-page":"4999","DOI":"10.1182\/blood-2024-198475","article-title":"Exploring the patient perspective of gene therapy for sickle cell disease","volume":"144","author":"Nimura","year":"2024","journal-title":"Blood."},{"key":"10.1016\/j.jtct.2026.03.037_bib0039","unstructured":"Clinical Review Report: Voretigene Neparvovec (Luxturna): (Novartis Pharmaceuticals Canada Inc.): Indication: Vision loss, inherited retinal dystrophy [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Jan. Stakeholder Engagement. Available at: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK569029\/. Accessed January 18, 2026."},{"key":"10.1016\/j.jtct.2026.03.037_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2025.106140","article-title":"585PDelphi consensus project to determine the meaningful treatment outcomes in adult spinal muscular atrophy (SMA)","volume":"53","author":"Costa","year":"2025","journal-title":"Neuromuscul Disord."},{"key":"10.1016\/j.jtct.2026.03.037_bib0041","doi-asserted-by":"crossref","DOI":"10.2340\/jrm.v57.41254","article-title":"An exploratory qualitative assessment of patient and clinician perspectives on patient-reported outcome measures and disease-modifying therapies in adults with spinal muscular atrophy","volume":"57","author":"Slayter","year":"2025","journal-title":"J Rehabil Med."},{"issue":"11","key":"10.1016\/j.jtct.2026.03.037_bib0042","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtct.2023.08.011","article-title":"The cell and gene therapy consortium\u2019s perspective on harmonizing data collection for patient enrollment, therapy ordering and scheduling, and cell collection","volume":"29","author":"Mora","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.03.037_bib0043","unstructured":"CIBMTR. CMS Innovation Center's Cell and Gene Therapy (CGT) Access Model for Sickle Cell Disease (SCD). Available at: https:\/\/cibmtr.org\/CIBMTR\/Collaborations\/CMMI. Accessed XXX."},{"issue":"6","key":"10.1016\/j.jtct.2026.03.037_bib0044","doi-asserted-by":"crossref","first-page":"349.e1","DOI":"10.1016\/j.jtct.2025.02.009","article-title":"Awakening from REMS: ASTCT 80\/20 Ongoing Recommendations for Safe Use of Chimeric Antigen Receptor T Cells","volume":"31","author":"Locke","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.03.037_bib0045","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jtct.2023.01.021","volume":"29","author":"Nikiforow","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"10.1016\/j.jtct.2026.03.037_bib0046","unstructured":"Tufts Medicine - Center for Biomedical System Design (NEWDIGS FoCUS Project). Pipeline analysis. Available at: https:\/\/newdigs.tuftsmedicalcenter.org\/payingforcures\/#gsc.tab=0. Accessed January 18, 2026."},{"issue":"12","key":"10.1016\/j.jtct.2026.03.037_bib0047","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1016\/j.ymthe.2018.10.017","article-title":"Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments","volume":"26","author":"Salzman","year":"2018","journal-title":"Mol Ther."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:36:45Z","timestamp":1785415005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2666636726002538"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.037","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value\u2011Based Contracting for Cell and Gene Therapies: A Scoping Review of Payer-Manufacturer Agreements and Treatment Center Considerations in the United States","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}